RCRafaela Ceron

Rafaela Ceron

*This is an algorithmically generated author record based on publicly available information.

Rafaela Ceron has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Increased Osteocyte Lacunae Size and Organic Matrix Pyridinoline Content in Transiliac Bone from Patients with Axial Spondyloarthritis (axSpA)

    by Barbara M. Misof, Natalia P. Machado, Shibarjun Mandal, Markus A. Hartmann, Rafaela Ceron, Marcelo M. Pinheiro, Eleftherios P. Paschalis, Stéphane Blouin, Carolina A. Moreira

    Axial spondyloarthritis (axSpA) is a chronic inflammation disorder commonly associated with osteoporosis and fractures. For further information about the pathophysiology of the latter, we analyzed transiliac biopsy samples from n = 21 men with axSpA (age 46 ± 6 years, mean ± SD). This cohort comprised patients with (GROUP-1, n = 5) or without increased osteoid thickness and mineralization lag time by histology (GROUP-2, n = 16). We performed quantitative backscattered electron imaging for bone mineralization density distribution (BMDD) and osteocyte lacunae sections (OLS), and Raman microspectroscopy for bone material/compositional properties in cancellous (Cn.) and cortical (Ct.) bone compartments. Patients’ outcomes were compared to different respective reference (REF)/control (CTRL) data. The total cohort and subgroup GROUP-1 (considered separately) showed significant deviations in BMDD versus REF. The average degree of cancellous bone mineralization was decreased by − 1.8% (p < 0.05) in the total cohort and decreased by − 5.1% (p < 0.01) in GROUP-1, while GROUP-2 had normal BMDD. The total cohort and both subgroups showed abnormal osteocyte OLS-characteristics. Specifically, the respective increases in OLS-area in cancellous and cortical bone were + 14.4% and + 44.5% in GROUP-1 and + 8.8% and + 24.9% in GROUP-2. The total cohort as well as both subgroups showed additionally deviations in organic matrix properties from CTRL with an increased pyridinoline content versus CTRL in both the cohort and subgroups. Our findings showed abnormal bone matrix mineralization in these patients with axSpA, with the largest deviations in the subgroup with histologically defined mineralization defects. The also observed altered osteocyte morphology and pyridinoline content might suggest osteocyte and osteoblast functional abnormalities in axSpA.

  • Open Access

    Effect of an oral antidiabetic, sitagliptin, a DPP-4 inhibitor, on bone remodeling: study in ovariectomized rats

    by Luciana Muniz Pechmann, Vicente Florentino Castaldo Andrade, Thais Andrade Costa Casagrande, Rafaela Ceron, Leticia Capote dos Santos, Edneia Amancio de Souza Ramos Cavalieiri, Gabriela Casani Cardoso, Regiane Stafim da Cunha, Carolina Aguiar Moreira

    Objective: To evaluate the effects of sitagliptin, a DPP-4 inhibitor, on bone remodeling using dynamic histomorphometry and assess DPP4 gene expression in bone tissue of ovariectomized (OVX) rats, a model of hypoestrogenism. Method: Non-diabetic female Wistar rats were divided into five groups: OVX-S (ovariectomized, sitagliptin-treated, n=9), OVX (ovariectomized, saline-treated, n=7), SHAM-S (sham-operated, sitagliptin-treated, n=10), SHAM (sham-operated, saline-treated, n=7), and control (n=7). Sitagliptin (25 mg/kg) or saline was administered daily via gavage for 13 weeks post-surgery. Bone histomorphometry of the right tibia assessed structural (BV/TV, Tb.Th, Tb.Sp, Tb.N), remodeling static (OS/BS, O.Th, ES/BS) and dynamic (MS/BS, MAR, BFR/BS) parameters. DPP4 gene expression in the right femur was analyzed using RT-qPCR. Statistical analyses included ANCOVA and Kruskal-Wallis tests (p<0.05). Results: Sitagliptin mitigated bone resorption in OVX-S compared to OVX. Structural parameters showed lower BV/TV and Tb.N, and higher Tb.Sp in OVX and OVX-S versus SHAM, SHAM-S, and control, with OVX-S having smaller Tb.Sp than OVX (p=0.012). Static parameters indicated higher OS/BS in OVX-S versus SHAM-S (p<0.04). Dynamic parameters revealed that the ovariectomized (OVX) group demonstrated greater number of fluorescent labels and therefore a higher mineralized surface (MS/BS) than the OVX-S (p<0.01), indicative that sitagliptin effectively mitigated increased bone resorption associated with hypoestrogenism. Dynamic parameters also revealed greater BFR/BS in OVX compared to all groups (p<0.001). DPP4 expression was significantly lower in OVX-S and SHAM-S versus OVX (p<0.01). Conclusion: Sitagliptin reduces bone remodeling in hypoestrogenic states, likely by decreasing resorption, as shown by histomorphometry and reduced DPP4 expression, suggesting its potential to prevent bone loss in conditions like menopause.

  • Open Access

    Efeitos protetores da melatonina no osso em ratas ovariectomizadas: insights a partir da histomorfometria

    by Fatima Sandmann Afonso, Rafaela Ceron, Angela Maria Reck, Leticia Capote dos Santos, Lorena Bavia, Maritana Mela Prodocimo, Liliane Roskamp, Thais Andrade Costa Casagrande, Vicente Florentino Castaldo Andrade, Carolina Aguiar Moreira

    Objetivo: Avaliar os efeitos da melatonina sobre parâmetros estruturais e de remodelação nas tíbias de ratas fêmeas Wistar ovariectomizadas (OVX) e submetidas à cirurgia SHAM. Métodos: Sessenta ratas Wistar foram submetidas à cirurgia de OVX (n=30) ou cirurgia SHAM (n=30) com 20 semanas de idade. Após a cirurgia, cada grupo foi dividido em três subgrupos (n=10) que receberam melatonina na dose 20 mg/kg, 50 mg/kg ou placebo por gavagem oral por 8 semanas, iniciadas 12 semanas após a cirurgia. Quando os animais atingiram 40 semanas de idade, as tíbias foram coletadas para análise histomorfométrica. Resultados: Ambas as doses (20 e 50 mg/kg) mantiveram a fração de volume ósseo (BV/TV). A dose de 50 mg/kg preservou o número de trabéculas (Tb.N), a separação entre as trabéculas (Tb.Sp) e reduziu significativamente a superfície erodida (ES/BS), evidenciando preservação da microarquitetura óssea e diminuição da reabsorção. Em ratas SHAM, a melatonina na dose de 50 mg/kg também reduziu ES/BS. Não foi observada correlação entre peso corporal e parâmetros ósseos. Os níveis de HbA1c foram significativamente menores nas ratas OVX tratadas com melatonina em ambas as doses. Não foram observadas alterações significativas em outros marcadores bioquímicos ou nos níveis de CTX. Conclusão: A melatonina, particularmente na dose de 50 mg/kg, preservou significativamente a microarquitetura óssea e atenuou a perda óssea em ratas OVX. Seu efeito limitado em ratas SHAM evidencia que a eficácia da melatonina é maior em condições de deficiência estrogênica. Esses achados destacam o potencial da melatonina como agente terapêutico para a perda óssea e as complicações metabólicas relacionadas à menopausa, apoiando a realização de pesquisas translacionais adicionais.